In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NeoChord Inc.

www.neochord.com

Latest From NeoChord Inc.

Harpoon Finds Its Whale: Edwards Spends Up To $250m For Beating-Heart Mitral Repair Option

Edwards Lifesciences exercised a 2015 option to buy Harpoon, a spin-off from the University of Maryland's School of Medicine, for $100m up-front and up to $150m more in milestones, to add Harpoon's beating-heart mitral valve surgery technology to its growing pipeline of transcatheter and surgical mitral valve repair and replacement devices. The deal also validates the investing approach of Epidarex Capital, one of Harpoon's early investors, which looks for early-stage medtech opportunities in the Mid-Atlantic states.

M & A Cardiology

Transcatheter Systems Set To Dominate Heart Valve Market

Less invasive transcatheter techniques will increasingly displace older, riskier open-heart procedures in the treatment of heart valve disease, according to a new Meddevicetracker report. By 2021, transcatheter systems will account for 76% of the global market for heart valve disease treatment products, with the US retaining its current dominant position in this sector.

Medical Device Market Intelligence

Market Intel: Relentless Rise Of Transcatheter Tech: Heart Valve Repair Turns Back On Open Surgery

The global market for products treating heart valve disease is expected to exceed $8bn by 2021, driven largely by the rising number of elderly patients with cardiovascular disease, obesity and growing prevalence of diabetes. This, in turn, is fueling significant innovation in minimally invasive techniques, particularly in the leading area of transcatheter aortic valve replacement (TAVR), but also in transcatheter mitral valve repair (TMVrep) systems, both of which offer patients quicker recovery times, less discomfort and greater safety compared to traditional surgical heart valve repair and replacement. This feature looks more closely at the competitive landscape and dynamics of these two fast-growing market segments, as well as gives insight into what the users – the physicians – think of these technologies.

Cardiovascular Surgical Procedures

Medtech Execs On The Move, May 2016

Recent executive-level company changes and promotions in the medical device and diagnostics industries.

See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • mValve Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • NeoChord Inc.
  • Senior Management
  • David Chung, CEO
    Shelley Chase Olsen, CFO
    John Zentgraf, VP, R&D
  • Contact Info
  • NeoChord Inc.
    Phone: (952) 653-1305
    11100 Bren Rd. W.
    Minnetonka, MN 55343
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register